Targeted drug palbociclib tested against cancers with specific genetic flaw
NCT ID NCT04439201
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study is for patients with solid tumors or lymphomas that have not responded to other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Palbociclib (a targeted cancer drug that blocks CDK4 and CDK6 proteins)
- What this could lead to
- If successful, this could provide a new treatment option for patients with certain genetic changes in their tumors, potentially shrinking or slowing cancer growth.
- What could go wrong
- This is a small, early-phase trial (40 patients) with no control group, so results may not apply broadly. The drug may not work for all tumor types, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer reveal hidden immune clues in tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?
- Can a Two-Step stem cell transplant tame Graft-Versus-Host disease?
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma